ENDRA Life Sciences (NDRA) Competitors

ENDRA Life Sciences (NASDAQ:NDRA) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Which has more risk and volatility, NDRA or POAI?

ENDRA Life Sciences has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Which has preferable earnings & valuation, NDRA or POAI?

ENDRA Life Sciences has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$10.06M	-$624.72	-0.01
Predictive Oncology	$1.62M	5.94	-$13.98M	-$3.05	-0.35

Does the media prefer NDRA or POAI?

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 3 articles in the media. Predictive Oncology's average media sentiment score of 0.96 beat ENDRA Life Sciences' score of 0.29 indicating that Predictive Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate NDRA or POAI?

ENDRA Life Sciences presently has a consensus target price of $50.00, indicating a potential upside of 708.28%. Predictive Oncology has a consensus target price of $3.00, indicating a potential upside of 177.78%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do insiders & institutionals have more ownership in NDRA or POAI?

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 3.4% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is NDRA or POAI more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -1,012.32%. ENDRA Life Sciences' return on equity of -127.39% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-127.39%	-103.77%
Predictive Oncology	-1,012.32%	-286.30%	-122.11%

Does the MarketBeat Community believe in NDRA or POAI?

ENDRA Life Sciences received 88 more outperform votes than Predictive Oncology when rated by MarketBeat users. However, 64.22% of users gave Predictive Oncology an outperform vote while only 62.86% of users gave ENDRA Life Sciences an outperform vote.

Company	Underperform	Outperform
ENDRA Life Sciences	Outperform Votes 237 62.86%	Underperform Votes 140 37.14%
Predictive Oncology	Outperform Votes 149 64.22%	Underperform Votes 83 35.78%

Summary

ENDRA Life Sciences beats Predictive Oncology on 9 of the 16 factors compared between the two stocks.